Project/Area Number |
22K17010
|
Research Category |
Grant-in-Aid for Early-Career Scientists
|
Allocation Type | Multi-year Fund |
Review Section |
Basic Section 57020:Oral pathobiological science-related
|
Research Institution | Hokkaido University |
Principal Investigator |
ハビバ ウンマ 北海道大学, 医学研究院, 客員研究員 (40755914)
|
Project Period (FY) |
2022-04-01 – 2025-03-31
|
Project Status |
Granted (Fiscal Year 2022)
|
Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2024: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2023: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2022: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Keywords | cancer stem cells (CSCs) / DN gels / drug-resistant / keyworad / cancer stem cells / head and neck cancer / hydrogel / reprogramming |
Outline of Research at the Start |
Cancer recurrence can arise due to rare circulating cancer stem cells (CSCs) resistant to chemotherapies and radiotherapies. This research focuses on the induction of head and neck cancer stem cells (HNCSCs) using hydrogel as a biomaterial. This study will develop suitable methods for detecting HNCSCs to create a personalized therapeutic modality. The study aims are:
1. Investigation of the mechanism of HNCSCs induction by the hydrogel. 2. Development of a diagnostic method for HNCSCs. 3. Establishment of a drug screening system for clinical application.
|
Outline of Annual Research Achievements |
Cancer recurrence can arise due to rare circulating cancer stem cells (CSCs) resistant to chemotherapies and radiotherapies. This research focuses on the induction of head and neck cancer stem cells (HNCSCs) using hydrogel as a biomaterial. The study aims to Investigate the mechanism of HNCSCs induction by the hydrogel, to develop a diagnostic method for HNCSCs, and to establish a drug screening system for clinical application. Our laboratory reported that a double-network hydrogel (DN gels), developed by Hokkaido University (Laboratory of Soft and Wet Matter), rapidly reprogrammed differentiated cancer cells into CSCs. The proposed study will be the first to use this principle to elucidate the mechanism of hydrogel-induced reprogramming of cancer cell populations to identify new CSC markers of HNSCC. Our research milestone for the fiscal year 2022 was to Elucidate the mechanism of induction of CSCs by the hydrogel. We characterized the hydrogel-induced sphere forming Head neck squamous carcinoma cells. We used four HNSCC cells (HSC2, HSC3, HSC4, Ca922) and cultured them on DN gels for five days. By Real-time PCR, we checked cancer stem cell markers (SOX-2, Nanog, OCt3/4, ALDH1) expression at 1-, 3-, and 5-day intervals. All cancer stem cell markers show their elevated expression as time elapses. From this data, we understand that DN gels rapidly reprogrammed differentiated Head and neck cancer cells into HNCSCs.
|
Current Status of Research Progress |
Current Status of Research Progress
3: Progress in research has been slightly delayed.
Reason
Currently, I can not do research as a full-time researcher. Due to my job responsibility, current research progress is slightly delayed. However, I could speed up my research from September 2023 onward.
|
Strategy for Future Research Activity |
2023-2024 Fiscal Year Plan: (I) To elucidate the mechanism of induction of CSCs by hydrogel by analysis of mechanosignal molecules and by genome/epigenome analysis (II) To develop a CSC diagnostic method using hydrogel by Identifying new CSC markers (Microarray and RNAseq analysis will be performed) and creating a personalized medical hydrogel kit using Patient-derived primary cultured cells to determine hydrogel conditions that can predict human tumors' recurrence profile after treatment. (III) To create seeds for CSC therapy using hydrogel by developing a drug screening system and identifying seeds using a hydrogel plate, we will do the drug screening, intending to obtain drug seeds that can be applied to medical treatment by performing large-scale screening targeting CSCs.
|